NCT03425838: Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone Receptor Positive Advanced Breast Cancer

NCT03425838
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 3
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must be treatment naïve, having never been treated with any systemic anti-cancer therapy, with the exception of recently started (within 28 days of randomization) endocrine therapy.
Exclusions: Active uncontrolled or symptomatic CNS metastases- see trial for details; Patients with prior treatment with any CDK4/6 inhibitor
https://ClinicalTrials.gov/show/NCT03425838

Comments are closed.

Up ↑